Involvement of Pro- and Anti-Inflammatory Cytokines and Chemokines in the Pathophysiology of Traumatic Brain Injury

Neurotherapeutics

Volumn 7, Issue 1, 2010, Pages 22-30

  Ziebell, Jenna M ^a   Morganti Kossmann, Maria Cristina ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

chemokines; cytokines; human TBI; Inflammation; traumatic brain injury

Indexed keywords

CHEMOKINE; CORTICOSTEROID; CYTOKINE; DEXANABINOL; ERYTHROPOIETIN; FAS LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR BINDING PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; GENE DELETION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; BRAIN INJURIES; CHEMOKINES; CYTOKINES; HUMANS; MODELS, NEUROLOGICAL;

EID: 72949092495     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.10.016     Document Type: Article

References (100)

1. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 14 (2004) 215-222
2. Morganti-Kossmann M.C., Rancan M., Otto V.I., Stahel P.F., and Kossmann T. Role of cerebral inflammation after traumatic brain injury: a revisited concept. Shock 16 (2001) 165-177
3. Correale J., and Villa A. The neuroprotective role of inflammation in nervous system injuries. J Neurol 251 (2004) 1304-1316
4. Bye N., Habgood M.D., Callaway J.K., et al. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol 204 (2007) 220-233
5. McIntosh T.K., Saatman K.E., Raghupathi R., et al. The Dorothy Russell Memorial Lecture. The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms. Neuropathol Appl Neurobiol 24 (1998) 251-267
6. Clark R.S., Schiding J.K., Kaczorowski S.L., Marion D.W., and Kochanek P.M. Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma 11 (1994) 499-506
7. Kato H., and Walz W. The initiation of the microglial response. Brain Pathol 10 (2000) 137-143
8. Kubes P., and Ward P.A. Leukocyte recruitment and the acute inflammatory response. Brain Pathol 10 (2000) 127-135
9. Perry R.T., Collins J.S., Wiener H., Acton R., and Go R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 22 (2001) 873-883
10. Werner C., and Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 99 (2007) 4-9
11. Lucas S.M., Rothwell N.J., and Gibson R.M. The role of inflammation in CNS injury and disease. Br J Pharmacol 147 Suppl 1 (2006) S232-S240
12. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19 (1996) 312-318
13. Bush T.G., Puvanachandra N., Horner C.H., et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23 (1999) 297-308
14. Tanno H., Nockels R.P., Pitts L.H., and Noble L.J. Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: Distribution and time course of protein extravasation. J Neurotrauma 9 (1992) 21-32
15. Habgood M.D., Bye N., Dziegielewska K.M., et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci 25 (2007) 231-238
16. Rothwell N.J. Annual review prize lecture. Cytokines: killers in the brain?. J Physiol 514 (1999) 3-17
17. Wang C.X., and Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 67 (2002) 161-172
18. Lu W., Gersting J.A., Maheshwari A., Christensen R.D., and Calhoun D.A. Developmental expression of chemokine receptor genes in the human fetus. Early Hum Dev 81 (2005) 489-496
19. Kielian T., and Hickey W.F. Proinflammatory cytokine, chemokine, and cellular adhesion molecule expression during the acute phase of experimental brain abscess development. Am J Pathol 157 (2000) 647-658
20. Semple B.D., Kossmann T., and Morganti-Kossmann M.C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab (2009 Nov 11) [Epub ahead of print]
21. Fan L., Young P.R., Barone F.C., Feuerstein G.Z., Smith D.H., and McIntosh T.K. Experimental brain injury induces expression of interleukin-1β mRNA in the rat brain. Brain Res Mol Brain Res 30 (1995) 125-130
22. Boraschi D., Bossù P., Ruggiero P., et al. Mapping of receptor binding sites on IL-1β by reconstruction of IL-1ra-like domains. J Immunol 155 (1995) 4719-4725
23. Winter C.D., Iannotti F., Pringle A.K., Trikkas C., Clough G.F., and Church M.K. A microdialysis method for the recovery of IL-1β, IL-6 and nerve growth factor from human brain in vivo. J Neurosci Methods 119 (2002) 45-50
24. Woodroofe M.N., Sarna G.S., Wadhwa M., et al. Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J Neuroimmunol 33 (1991) 227-236
25. Knoblach S.M., and Faden A.I. Cortical interleukin-1β elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery. Neurosci Lett 289 (2000) 5-8
26. Loddick S.A., and Rothwell N.J. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 16 (1996) 932-940
27. Relton J.K., and Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 29 (1992) 243-246
28. Crack P.J., Gould J., Bye N., et al. The genomic profile of the cerebral cortex after closed head injury in mice: effects of minocycline. J Neural Transm 116 (2009) 1-12
29. Sanchez Mejia R.O., Ona V.O., Li M., and Friedlander R.M. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48 (2001) 1393-1399 discussion 1399-1401
30. Hammacher A., Ward L.D., Weinstock J., Treutlein H., Yasukawa K., and Simpson R.J. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Protein Sci 3 (1994) 2280-2293
31. Raivich G., Bohatschek M., Kloss C.U., Werner A., Jones L.L., and Kreutzberg G.W. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev 30 (1999) 77-105
32. Hopkins S.J., and Rothwell N.J. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci 18 (1995) 83-88
33. Benveniste E.N. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 9 (1998) 259-275
34. Kossmann T., Hans V.H., Imhof H.G., et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 4 (1995) 311-317
35. Shohami E., Novikov M., Bass R., Yamin A., and Gallily R. Closed head injury triggers early production of TNFα and IL-6 by brain tissue. J Cereb Blood Flow Metab 14 (1994) 615-619
36. Taupin V., Toulmond S., Serrano A., Benavides J., and Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion: influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol 42 (1993) 177-185
37. Penkowa M., Camats J., Hadberg H., et al. Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J Neurosci Res 73 (2003) 481-496
38. Penkowa M., Giralt M., Carrasco J., Hadberg H., and Hidalgo J. Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia 32 (2000) 271-285
39. Meager A. The molecular biology of cytokines (1998), Wiley, New York
40. 2 on tumor necrosis factor and interleukin-10 production in microglia: a regulatory loop controlling microglia pro- and anti-inflammatory activities. J Neurosci Res 56 (1999) 571-580
41. Mesples B., Plaisant F., and Gressens P. Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice. Brain Res Dev Brain Res 141 (2003) 25-32
42. Wu Z., Zhang J., and Nakanishi H. Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation. J Neuroimmunol 167 (2005) 90-98
43. Knoblach S.M., and Faden A.I. Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol 153 (1998) 143-151
44. Kremlev S.G., and Palmer C. Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J Neuroimmunol 162 (2005) 71-80
45. Csuka E., Morganti-Kossmann M.C., Lenzlinger P.M., Joller H., Trentz O., and Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-α, TGF-β1 and blood-brain barrier function. J Neuroimmunol 101 (1999) 211-221
46. Lyng K., Munkeby B.H., Saugstad O.D., Stray-Pedersen B., and Frøen J.F. Effect of interleukin-10 on newborn piglet brain following hypoxia-ischemia and endotoxin-induced inflammation. Biol Neonate 87 (2005) 207-216
47. Bell M.J., Kochanek P.M., Doughty L.A., et al. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma 14 (1997) 451-457
48. Breder C.D., Tsujimoto M., Terano Y., Scott D.W., and Saper C.B. Distribution and characterization of tumor necrosis factor-α-like immunoreactivity in the murine central nervous system. J Comp Neurol 337 (1993) 543-567
49. Allan S.M., and Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2 (2001) 734-744
50. Chao C.C., Hu S., Ehrlich L., and Peterson P.K. Interleukin-1 and tumor necrosis factor-α synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-d-aspartate receptors. Brain Behav Immun 9 (1995) 355-365
51. Shohami E., Gallily R., Mechoulam R., Bass R., and Ben-Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol 72 (1997) 169-177
52. Riva-Depaty I., Fardeau C., Mariani J., Bouchaud C., and Delhaye-Bouchaud N. Contribution of peripheral macrophages and microglia to the cellular reaction after mechanical or neurotoxin-induced lesions of the rat brain. Exp Neurol 128 (1994) 77-87
53. Csuka E., Hans V.H., Ammann E., Trentz O., Kossmann T., and Morganti-Kossmann M.C. Cell activation and inflammatory response following traumatic axonal injury in the rat. Neuroreport 11 (2000) 2587-2590
54. Knoblach S.M., Fan L., and Faden A.I. Early neuronal expression of tumor necrosis factor-α after experimental brain injury contributes to neurological impairment. J Neuroimmunol 95 (1999) 115-125
55. Kim K.S., Wass C.A., Cross A.S., and Opal S.M. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res 11 (1992) 293-298
56. Ramilo O., Sáez-Llorens X., Mertsola J., et al. Tumor necrosis factor α/cachectin and interleukin 1 β initiate meningeal inflammation. J Exp Med 172 (1990) 497-507
57. Maas A.I., Murray G., Henney III H., et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 5 (2006) 38-45
58. Scherbel U., Raghupathi R., Nakamura M., et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A 96 (1999) 8721-8726
59. Stahel P.F., Shohami E., Younis F.M., et al. Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. J Cereb Blood Flow Metab 20 (2000) 369-380
60. Sullivan P.G., Bruce-Keller A.J., Rabchevsky A.G., et al. Exacerbation of damage and altered NF-κB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci 19 (1999) 6248-6256
61. Itoh N., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 (1991) 233-243
62. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
63. Suda T., Takahashi T., Golstein P., and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178
64. Choi C., Park J.Y., Lee J., et al. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ. J Immunol 162 (1999) 1889-1895
65. Beer R., Franz G., Schöpf M., et al. Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat. J Cereb Blood Flow Metab 20 (2000) 669-677
66. Grosjean M.B., Lenzlinger P.M., Stahel P.F., et al. Immunohistochemical characterization of Fas (CD95) and Fas ligand (FasL/CD95L) expression in the injured brain: relationship with neuronal cell death and inflammatory mediators. Histol Histopathol 22 (2007) 235-250
67. Martin-Villalba A., Herr I., Jeremias I., et al. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19 (1999) 3809-3817
68. Qiu J., Whalen M.J., Lowenstein P., et al. Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci 22 (2002) 3504-3511
69. Rosenbaum D.M., Gupta G., D'Amore J., et al. Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. J Neurosci Res 61 (2000) 686-692
70. Tanaka M., Suda T., Takahashi T., and Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 14 (1995) 1129-1135
71. Ertel W., Keel M., Stocker R., et al. Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury. J Neuroimmunol 80 (1997) 93-96
72. Lenzlinger P.M., Marx A., Trentz O., Kossmann T., and Morganti-Kossmann M.C. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J Neuroimmunol 122 (2002) 167-174
73. Park D.R., Thomsen A.R., Frevert C.W., et al. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 170 (2003) 6209-6216
74. Baggiolini M., Walz A., and Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84 (1989) 1045-1049
75. Smith W.B., Gamble J.R., Clark-Lewis I., and Vadas M.A. Interleukin-8 induces neutrophil transendothelial migration. Immunology 72 (1991) 65-72
76. Zwijnenburg P.J., Polfliet M.M., Florquin S., et al. CXC-chemokines KC and macrophage inflammatory protein-2 (MIP-2) synergistically induce leukocyte recruitment to the central nervous system in rats. Immunol Lett 85 (2003) 1-4
77. Aloisi F., Carè A., Borsellino G., et al. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1β and tumor necrosis factor-α. J Immunol 149 (1992) 2358-2366
78. Whalen M.J., Carlos T.M., Kochanek P.M., et al. Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit Care Med 28 (2000) 929-934
79. Morganti-Kossmann M.C., Lenzlinger P.M., Hans V., et al. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 2 (1997) 133-136
80. Yoshimura T., Robinson E.A., Tanaka S., Appella E., and Leonard E.J. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 142 (1989) 1956-1962
81. Glabinski A.R., Balasingam V., Tani M., et al. Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 156 (1996) 4363-4368
82. Banisadr G., et al. Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 81 (2002) 257-269
83. Rankine E.L., Hughes P.M., Botham M.S., Perry V.H., and Felton L.M. Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. Eur J Neurosci 24 (2006) 77-86
84. Gourmala N.G., Buttini M., Limonta S., Sauter A., and Boddeke H.W. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 74 (1997) 35-44
85. Galasso J.M., Miller M.J., Cowell R.M., Harrison J.K., Warren J.S., and Silverstein F.S. Acute excitotoxic injury induces expression of monocyte chemoattractant protein-1 and its receptor, CCR2, in neonatal rat brain. Exp Neurol 165 (2000) 295-305
86. Hughes P.M., Allegrini P.R., Rudin M., Perry V.H., Mir A.K., and Wiessner C. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 22 (2002) 308-317
87. Lu B., Rutledge B.J., Gu L., et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187 (1998) 601-608
88. Edwards P., Arango M., Balica L., et al., CRASH trial collaborators. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury: outcomes at 6 months. Lancet 365 (2005) 1957-1959
89. Breitner J.C., Welsh K.A., and Helms M.J. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16 (1995) 523-530
90. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 (2003) 128
91. Townsend K.P., and Praticò D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19 (2005) 1592-1601
92. Browne K.D., Iwata A., Putt M.E., and Smith D.H. Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats. Exp Neurol 201 (2006) 301-307
93. Alano C.C., Kauppinen T.M., Valls A.V., and Swanson R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 103 (2006) 9685-9690
94. Maier B., Laurer H.L., Rose S., Buurman W.A., and Marzi I. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma 22 (2005) 822-835
95. Stirling D.P., Khodarahmi K., Liu J., et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24 (2004) 2182-2190
96. Xu L., Fagan S.C., Waller J.L., et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 4 (2004) 7
97. Lawrence C.B., Allan S.M., and Rothwell N.J. Interleukin-1β and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 10 (1998) 1188-1195
98. Fattori E., Lazzaro D., Musiani P., Modesti A., Alonzi T., and Ciliberto G. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci 7 (1995) 2441-2449
99. Schneider A., Krüger C., Steigleder T., et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115 (2005) 2083-2098
100. Sehara Y., Hayashi T., Deguchi K., et al. Potentiation of neurogenesis and angiogenesis by G-CSF after focal cerebral ischemia in rats. Brain Res 1151 (2007) 142-149